Lung Cancer · 2022 · 20 citations · 17 references
PharmacyOncologyEvidence-based PracticeHealthcare Quality ImprovementOutcomes ResearchClinical Outcome AssessmentHealth Outcomes MeasurementOutcome AssessmentOutcome MeasurementPatient-reported Outcome MeasuresPatient-reported OutcomesHealth Outcomes AnalysisPatient Outcome EvaluationPatient Outcome MeasurementPatient-reported Outcome Measure ValidationPatient-reported Outcome MeasurementPatient-reported Outcome ReportingPatient-reported Outcome StandardsPotential Outcomes
BACKGROUND: In 2016, the International Consortium for Health Outcomes Measurement (ICHOM) defined an international consensus recommendation of the most important outcomes for lung cancer patients. The European Health Outcomes Observatory (H2O) initiative aimed to develop an updated patient-centered core outcome set (COS) for lung cancer, to capture the patient perspective of the impact of lung cancer and (novel) treatments using a combination of patient-reported outcome (PRO) instruments and clinical data as a means to drive value-based health-care. MATERIAL AND METHODS: An international, expert team of patient representatives, multidisciplinary healthcare professionals, academic researchers and pharmaceutical industry representatives (n = 17) reviewed potential outcomes generated through literature review. A broader group of patients/patient representatives (n = 31), healthcare professionals / academic researchers (n = 83), pharmaceutical industry representatives (n = 26), and health authority representatives (n = 6) participated in a Delphi study. In two survey rounds, participants scored the relevance of outcomes from a preliminary list. The threshold for consensus was defined as ≥ 70 % of participants scoring an outcome as 'highly relevant'. In concluding consensus-meeting rounds, the expert multidisciplinary team finalized the COS. RESULTS: The preliminary list defined by the core group consisted of 102 outcomes and was prioritized in the Delphi procedure to 64. The final lung cancer COS includes: 1) case-mix factors (n = 27); 2) PROs related to health-related quality of life (HRQoL) (n = 25); 3) clinical outcomes (n = 12). Patient-reported symptoms beyond domains included in the ICHOM lung cancer set in 2016 were insomnia, nausea, vomiting, anxiety, depression, lack of appetite, gastric problems, constipation, diarrhoea, dysphagia, and haemoptysis. CONCLUSIONS: We will implement the lung cancer COS in Europe within the H2O initiative by collecting the outcomes through a combination of clinician-reported measures and PRO measures. The COS will support the adoption and reporting of lung cancer measures in a standardized way across Europe and empower patients with lung cancer to better manage their health care.
17
Claudia Allemani, Tomohiro Matsuda, V Di Carlo et al. · The Lancet · 2018 · 6.2K citations · Full text
Medicine, Biostatistics, Oncology +17
Cancer statistics for the year 2020: An overview
Jacques Ferlay, Murielle Colombet, Isabelle Soerjomataram et al. · International Journal of Cancer · 2021 · 5.7K citations · Full text
The Effect of Advances in Lung-Cancer Treatment on Population Mortality
Nadia Howlader, Gonçalo Forjaz, Meghan J. Mooradian et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text
Developing core outcome sets for clinical trials: issues to consider
Paula Williamson, Douglas G. Altman, Jane Blazeby et al. · Trials · 2012 · 1.7K citations · Full text